MRI Response Assessment in Patients with Glioblastoma Treated with Dendritic Cell-Based Immunotherapy
In glioblastoma (GB), patients’ reliable response assessment criteria are crucial in order to accurately compare the responsiveness of different therapies in clinical trials, and to differentiate between therapy-induced changes and true tumour progression.